Low-dose radiation therapy is linked with improved progression-free survival in patients with advanced Hodgkin lymphoma (HL), according to a study involving 90 individuals. This is the case even in those who experience complete metabolic response after adriamycin, bleomycin, vinblastine, dacarbazine (ABVD). Participants had stage III-IV HL and were treated with either chemotherapy alone (n= 46) or combination therapy (n=44) between 1992 and 2012. Chemo regimen was mainly ABVD or a hybrid of it. Investigators looked at outcomes in those who achieved complete metabolic response. Among the results:
- 88% of patients receiving combo therapy experienced 5-year progression-free survival, vs 65% of those who were given chemo alone.
- Overall survival rates were 97% and 78%, respectively.
- Patients <45 years of age and those receiving combination regimens were more likely to experience improved progression-free survival.
- Secondary malignancies were similar in both groups.
- Cardiac events occurred a bit more often in patients receiving combo regimens.
Song E, Torok J, Wu Y, et al. Consolidation radiation therapy for advanced Hodgkin lymphoma in complete metabolic response by PET-CT or gallium. [Published online ahead of print December 29, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.12.007.
This Week's Must Reads
Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.
QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.
Women less likely to receive industry funds, Weng JK et al. JAMA Netw Open. 2019 Jan. 25. doi: 10.1001/jamanetworkopen.2018.7377.
Must Reads in Hodgkin Lymphoma
Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.
Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.
PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.
Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.
Treatments for Advanced Hodgkin’s Lymphoma Studied, N Engl J Med; 2018 Jan 25; Connors, Jurczak, et al